JP2022550099A5 - - Google Patents

Info

Publication number
JP2022550099A5
JP2022550099A5 JP2022519289A JP2022519289A JP2022550099A5 JP 2022550099 A5 JP2022550099 A5 JP 2022550099A5 JP 2022519289 A JP2022519289 A JP 2022519289A JP 2022519289 A JP2022519289 A JP 2022519289A JP 2022550099 A5 JP2022550099 A5 JP 2022550099A5
Authority
JP
Japan
Prior art keywords
alkyl
cyano
halo
cycloalkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022519289A
Other languages
English (en)
Japanese (ja)
Other versions
JP7802655B2 (ja
JP2022550099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052789 external-priority patent/WO2021062199A1/en
Publication of JP2022550099A publication Critical patent/JP2022550099A/ja
Publication of JP2022550099A5 publication Critical patent/JP2022550099A5/ja
Priority to JP2025107082A priority Critical patent/JP2025138749A/ja
Application granted granted Critical
Publication of JP7802655B2 publication Critical patent/JP7802655B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022519289A 2019-09-27 2020-09-25 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤 Active JP7802655B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107082A JP2025138749A (ja) 2019-09-27 2025-06-25 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907146P 2019-09-27 2019-09-27
US62/907,146 2019-09-27
PCT/US2020/052789 WO2021062199A1 (en) 2019-09-27 2020-09-25 Inhibitors of receptor interacting protein kinase i for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107082A Division JP2025138749A (ja) 2019-09-27 2025-06-25 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤

Publications (3)

Publication Number Publication Date
JP2022550099A JP2022550099A (ja) 2022-11-30
JP2022550099A5 true JP2022550099A5 (cg-RX-API-DMAC7.html) 2023-09-26
JP7802655B2 JP7802655B2 (ja) 2026-01-20

Family

ID=75162965

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519289A Active JP7802655B2 (ja) 2019-09-27 2020-09-25 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤
JP2025107082A Pending JP2025138749A (ja) 2019-09-27 2025-06-25 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107082A Pending JP2025138749A (ja) 2019-09-27 2025-06-25 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤

Country Status (11)

Country Link
US (3) US11753381B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034530A4 (cg-RX-API-DMAC7.html)
JP (2) JP7802655B2 (cg-RX-API-DMAC7.html)
KR (1) KR102973172B1 (cg-RX-API-DMAC7.html)
CN (1) CN115605463B (cg-RX-API-DMAC7.html)
AU (1) AU2020353663B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022005627A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155259A1 (cg-RX-API-DMAC7.html)
IL (1) IL291665B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022003671A (cg-RX-API-DMAC7.html)
WO (1) WO2021062199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2020391425A1 (en) 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
CN115916755A (zh) 2020-05-20 2023-04-04 维泰瑞隆有限公司 氮杂环丁烷环状脲
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
CN116444437B (zh) * 2023-03-08 2025-09-16 曲靖师范学院 抗癌医药达洛鲁胺的合成方法
JP2026516095A (ja) * 2023-05-10 2026-05-19 ジェンザイム・コーポレーション Ripk1阻害剤としてのイソオキサゾリジン及びその使用
EP4709722A1 (en) * 2023-05-10 2026-03-18 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof
WO2025165774A1 (en) * 2024-02-01 2025-08-07 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
WO2026001865A1 (en) * 2024-06-24 2026-01-02 Sironax Ltd. Rip1 modulators, preparations, and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177188B1 (en) 1999-05-12 2005-10-12 Ortho-McNeil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
WO2012125544A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
SG11201404505PA (en) 2012-01-31 2014-10-30 Daiichi Sankyo Co Ltd Pyridone derivative
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
AU2014318837B2 (en) 2013-09-12 2019-05-30 Janssen Biopharma, Inc. Pyridazinone compounds and uses thereof
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Trpv4阻害活性を有する6員環誘導体
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
CN106999451B (zh) * 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
WO2016101887A1 (en) 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
EP3271365B1 (en) * 2015-03-20 2019-12-18 Pfizer Inc Bifunctional cytotoxic agents containing the cti pharmacophore
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
ES2916099T3 (es) * 2016-03-14 2022-06-28 Spirochem Ag Método de preparación de biciclo[1.1.1]pentanos sustituidos
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CN105785659B (zh) * 2016-05-20 2018-07-10 深圳市华星光电技术有限公司 含功能化石墨烯层的液晶面板结构及功能化石墨烯膜的制备方法
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ. ホフマン-ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
CA3045947A1 (en) 2016-12-08 2018-06-14 Michael J. Soth Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
SG10201913927VA (en) 2017-05-17 2020-03-30 Denali Therapeutics Inc Kinase inhibitors and uses thereof
CN109180681B (zh) * 2017-08-18 2021-08-20 四川百利药业有限责任公司 一种dna毒性二聚体化合物
US11339103B2 (en) * 2017-09-11 2022-05-24 Recurium Ip Holdings, Llc Continuous flow processes for making bicyclic compounds
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
EP3494994A1 (en) 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
EP3781571B1 (en) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
WO2019224773A1 (en) 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
US11560366B2 (en) * 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
AU2020391425A1 (en) 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
BR112022017099A2 (pt) 2020-02-28 2022-11-16 Univ Texas Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc

Similar Documents

Publication Publication Date Title
DE69833224T2 (de) Benzothiazole als protein tyrosin-kinase inhibitoren
NZ599860A (en) Carboxamide compounds and their use as calpain inhibitors
IL160522A (en) 1h - imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1-antagonistic activity
ZA202201505B (en) Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
SK286072B6 (sk) 1,2-anelované chinolínové deriváty, spôsob ich prípravy, medziprodukty, farmaceutický prostriedok aich použitie
JP2008535902A5 (cg-RX-API-DMAC7.html)
JP2004518723A5 (cg-RX-API-DMAC7.html)
RU2007146798A (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
JP2008535903A5 (cg-RX-API-DMAC7.html)
IL291665B2 (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
JP2010502717A5 (cg-RX-API-DMAC7.html)
AU2007235576A1 (en) Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
JP2011509309A5 (cg-RX-API-DMAC7.html)
HUP0304054A2 (hu) A kortikotropin-realising faktor (CRF) antagonistáiként alkalmazható kondenzált pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2017511378A5 (cg-RX-API-DMAC7.html)
RU2016108038A (ru) Новые фталазиновые производные и способ их получения
US11339122B2 (en) hTRPV1 chemical agents
US20040229927A1 (en) Imidazole derivatives for treatment of allergic and hyperproliferative disorders
JP2012507525A5 (cg-RX-API-DMAC7.html)
JP2010520168A5 (cg-RX-API-DMAC7.html)
JP2016534143A5 (cg-RX-API-DMAC7.html)
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
JP4450628B2 (ja) ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換2−キノリンおよびキナゾリン誘導体
JP2023552838A5 (cg-RX-API-DMAC7.html)